Cancer in the Immunosuppressed Patient
Authors: JOHN L. FAHEY
Journal: Annals of Internal Medicine (1971)

Editorials1 August 1971Cancer in the Immunosuppressed PatientJOHN L. FAHEY, M.D.JOHN L. FAHEY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-75-2-310 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptManipulation of normal body processes to achieve therapeutic benefit may lead to undesired and late appearing complications. This seems to be the case with induced immune suppression, where cancer develops as a late complication in some patients. Neoplastic disease in immunosuppressed patients is now documented at an incidence far higher (100 times greater) than would be expected in the general population. The clinical evidence is supported by observations in experimental animals. These findings point to the need to consider the possibility of this undesirable side effect before undertaking administration of drugs that may be immunosuppressive, as well as the need...References1. PENN I, HAMMOND W, and BRETTSCHNEIDER L: Malignant lymphomas in transplantation patients. Transplantation Proc 1:106-112, 1969 MedlineGoogle Scholar2. PENN I, HALGRIMSON C, and STARZL T: De novo malignant tumors in organ transplant recipients. Transplantation Proc. In press, March 1971 Google Scholar3. MCKHANN C: Primary malignancy in patients undergoing immunosuppression for renal transplantation. Transplantation 8:209-212, 1969 CrossrefMedlineGoogle Scholar4. PRITZKER K, HUANG S, and MARSHALL K: Malignant tumours following immunosuppressive therapy. Canad Med Ass J 103:1362-1365, 1970 MedlineGoogle Scholar5. PAGE A, HANSEN A, and GOOD R: Occurrence of leukemia and lymphoma in patients with agammaglobulinemia. Blood 21:197-206, 1963 CrossrefMedlineGoogle Scholar6. GOOD R, KELLEY W, and ROTSTEIN J: Immunological deficiency diseases. Progr Allergy 6:187-319, 1962 MedlineGoogle Scholar7. LAW L: Studies of the significance of tumor antigens in induction and repression of neoplastic diseases. Cancer Res 29:1-21, 1969 MedlineGoogle Scholar8. LAW L: Effects of antilymphocyte serum on the induction of neoplasms of lymphoreticular tissues. Fed Proc 29:171-174, 1970 MedlineGoogle Scholar9. ALLISON A, BERMAN L, and LEVEY R: Increased tumor induction by adenovirus type 12 in thymectomized mice and mice treated with anti-lymphocyte serum. Nature (London) 215:185-187, 1967 CrossrefMedlineGoogle Scholar10. ALLISON A and LAW L: Effects of antilymphocyte serum on viral oncogenesis. Proc Soc Exp Biol Med 127:207-212, 1968 CrossrefMedlineGoogle Scholar11. HUMPHREYS S, GLYNN J, and CHIRIGOS M: Further studies on the homograft response in BALB/c mice with L1210 leukemia and a resistant subline. J Nat Cancer Inst 28:1053-1063, 1962 MedlineGoogle Scholar12. REINER J and SOUTHAM C: Effect of immunosuppression on first generation isotransplantation of chemically induced tumors in mice. Nature (London) 210:429-430, 1966 CrossrefMedlineGoogle Scholar13. REINER J and SOUTHAM C: Increased growth of tumor isotransplants after immunosuppression of the recipient mice by methotrexate or 5-fluoro-2-deoxyuridine. J Nat Cancer Inst 38:753-759, 1967 MedlineGoogle Scholar14. BERGMAN S, JONSSON N, and AHLSTROM C: Infectious fibroma in prednisone treated rabbits. Acta Path Microbiol Scand 55:39-48, 1962 CrossrefGoogle Scholar15. HURST E: The effect of cortisone and of 6-mercaptopurine on the Shope fibroma. J Path Bact 87:29-37, 1964 CrossrefMedlineGoogle Scholar16. HOLECKOVA E, SOUKUPORA M, and SEKLA B: Effect of mercaptopurine on Walker 256 tumor homografts in resistant rats. Transplantation Bull 28:32-33, 1961 Google Scholar17. WILSON R, HOGER E, and HAMPERS C: Immunologic rejection of human cancer transplanted with a renal allograft. New Eng J Med 278:479-483, 1968 CrossrefMedlineGoogle Scholar18. : A controlled trial of cyclophosphamide in rheumatoid arthritis. New Eng J Med 283:883-889, 1970 CrossrefMedlineGoogle Scholar19. WEINSTEIN G and FROST P: Methotrexate for psoriasis. Arch Dermat (Chicago) 103:33-38, 1971 CrossrefMedlineGoogle Scholar20. HOBBS J: Paraproteinemia. Proc Roy Soc Med 62:773-776, 1969 CrossrefMedlineGoogle Scholar21. SCHWARTZ R and COSTEA N: Autoimmune hemolytic anemia. Clinical correlations and biological implications. Seminars Hemat 3:2-85, 1966 MedlineGoogle Scholar22. FIALKOW P: "Immunologic" oncogenesis. Blood 30:388-394, 1967 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JOHN L. FAHEY, M.D.Affiliations: Department of Medical Microbiology and Immunology UCLA School of Medicine Los Angeles, Calif. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTaxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesisKaposi sarcomaGlobal HIV/AIDS Burden and Associated DiseasesViral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other virusesAcute myeloid leukemia following solid organ transplantation: entity or novelty?Abnormal variation of the immune response as related to cancerRARE TUMOURS OF THE COLON AND RECTUMAutoimmune Hemolytic AnemiasInitial report of bladder carcinoma following combined bladder-drained pancreas and kidney transplantationExtrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitisAbnormal Variation of the Immune System as Related to CancerRheumatologic Manifestations of CancerPemphigus vulgaris and malignancyPemphigus associated diseases and induced pemphigusCutaneous Complications of Immunosuppressive AgentsMusculoskeletal syndromes associated with malignancySquamous cell carcinoma arising in pemphigus vulgaris during immunosuppressive therapyComparison of high and low dose cyclophosphamide therapy in rheumatoid arthritisLack of oncogenicity with immunosuppressive therapyAzathioprine and Subacute Myelomonocytic LeukemiaComparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritisAkute Leuk�mie nach NierentransplantationMalignant lymphoproliferative disorders in chronic liver diseaseOvarian carcinoma terminating in acute nonlymphocytic leukemia following alkylating agent therapyBullöse DermatosenA Cheap Oral Therapy for Paget's Disease of BoneExtrahepatic Malignancy in Chronic Liver Disease: Report of Six CasesChapter 15: Immunosuppressive and Immunostimulatory Agents in Rheumatoid ArthritisSquamous Cell Carcinoma of the Ureterovesical Junction after Renal TransplantationLeukemia in children with Wilms tumorImmunosuppressive Drugs: Mechanisms of Action, Toxicity and Clinical EffectsAdverse Reactions to Cytostatic AgentsProblems with immunosuppressive agents in renal diseaseAcute myelogenous leukemia in two patients treated with azathioprine for nonmalignant diseasesMalignancy in a series of 70 patients with systemic lupus erythematosusPemphigus vulgaris and internal malignancyAlkylating agents as leukemogens in multiple myelomaThe association of pemphigus with thymoma or malignancy: a critical reviewClinical Utility of Immunosuppressive AgentsLOSS OF SUPPRESSOR FUNCTION AS A CAUSE OF LYMPHOID MALIGNANCYAdditional Risk from Immunosuppressive Therapy for Rheumatoid ArthritisJOSEPH D. MCCRACKENNeoplasia and CyclophosphamideAcute leukemia complicating metastatic breast cancerToxicity of immunosuppressive drugs in manKoinzidenz von familiär gehäuft auftretendem Plasmozytom, chronischer lymphatischer Leukämie und RektumkarzinomInfectious diseases: annual review of significant publicationsCytotoxic Drugs in Treatment of Nonmalignant DiseasesALFRED D. STEINBERG, M.D., PAUL H. PLOTZ, M.D., SHELDON M. WOLFF, M.D., F.A.C.P., VERNON G. WONG, M.D., SAUL G. AGUS, M.D., JOHN L. DECKER, M.D., F.A.C.P.MANIPULATION OF THE IMMUNE RESPONSE TOWARDS IMMUNOTHERAPY OF CANCERSKIN CANCER AND IMMUNOSUPPRESSION 1 August 1971Volume 75, Issue 2Page: 310-312KeywordsAdverse reactionsCancer immunotherapyDrug administrationImmune suppressionImmunosuppressives ePublished: 1 December 2008 Issue Published: 1 August 1971 PDF downloadLoading ...